You Searched For "adar poonawalla wellness forever" and got 20 results
Sort By:
1 min read
Adar Poonawalla-backed pharmacy chain Wellness Forever files for IPO
Apart from a fresh issue worth up to ₹400 crore, there will be an Offer for Sale (OFS) wherein…
PTI
1 min read
Covovax vaccine to get approval as a booster in 10-15 days: Adar Poonawalla
Asked about states and districts not getting Covishield vaccine, he said there is ample stock wi…
PTI
3 mins read
US-based biotechnology company Novavax’s COVID-19 shot is 90% effective
US-based biotechnology company Novavax's protein-based vaccine has shown overall 90 per cent effica…
3 mins read
If 2015 was the ‘Year of the API’, why is there a Remdesivir shortage six years later?
Catchphrases don’t cure, actual drugs do. In fact, since 2015, the year when the government…
3 mins read
A drug retail chain grew from ₹8 crore a year to ₹1000 crore without the MSME tag— the founder has lessons to share with other small biz
An Indian drugs retail chain, and now a medtech platform, Wellness Forever, had an annual turnover …
3 mins read
Rivals Serum Institute and Bharat Biotech come together after fear of ban on vaccine exports
Bharat Biotech CEO Krishna Ella and Serum Institute of India (SII) CEO Adar Poonawalla issued a joi…
4 mins read
COVID-19 vaccine will be priced at ₹1,000 and would be available by February for healthcare workers and elderly people, says Serum CEO Adar Poonawalla
"It will probably take two or three years for every Indian to get inoculated, not just because o…
PTI
3 mins read
Coronavirus vaccine Covishield completes enrolment of phase-3 clinical trials under ICMR, Serum Institute's partnership
"The partnership is a stellar example of private-public institutes collaborating to mitigate the…
PTI
8 mins read
With a $2 million funding from Sachin Tendulkar, Rajan Navani of digital entertainment and tech company JetSynthesys shares the roadmap ahead
JetSynthesys will use the funding to strengthen its existing catalogue of products and platforms un…
2 mins read
Why there's little chance we'll have coronavirus vaccine data in October, according to JPMorgan
Business Insider's biggest healthcare stories for September 15.
Lydia Ramsey Pflanzer
3 mins read
The Oxford COVID-19 vaccine is 'progressing very well,' according to the lead scientists, who said 10,000 more people will be inoculated
Researchers at Oxford University said Friday that they would move on to the next phase of testing, …
Bill Bostock
4 mins read
Reliance, Tata on TIME's list of world's most influential companies
Serum Institute is the other Indian company on the list. TIME listed Reliance in the 'Tita…
PTI
1 min read
Kerala to have new quarantine rules for international travellers
Travellers from UK will have to undergo ten-day quarantine at home or destination address, accor…
3 mins read
DroneAcharya IPO subscribed 262x on last day as HNIs, retail investors lap it up
The IPO of DroneAcharya Aerial Innovations received an overwhelming investor interest, and was subs…
1 min read
Disney Plus mobile app exceeds $1.5 billion in worldwide consumer spending
Since its launch in 2019, Disney+ has entered a number of new markets, which has helped its mo…
1 min read
Samsung and LG battery units estimated to post tepid earnings in third quarter
Its brisk earnings are expected to be led by solid demand for electric vehicle (EV) battery …
3 mins read
Ice cubes to gulab jamuns and 50 lakh kilos of organic fruits and veggies – how India Swiggy’d in 2022
Swiggy’s latest annual trends report reveals just how dependent Indians have become on ordering foo…
4 mins read
Gautam Adani: Man of the year
Gautam Adani, India’s richest and the world’s third richest person, has been crowned ‘Asia’s busies…
1 min read
Govt panel recommends EUA for Covid vaccine Covovax for 12-17 age group
"This approval will not only be beneficial for our country alone, but will benefit the entire worl…
PTI
1 min read
SII seeks permission for phase-3 study of Covid vaccine Covovax as booster dose in adults
Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII had last week submitted an …